Testicular Sperm Aspiration (TESA) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Testicular Sperm Aspiration (TESA) is a minimally invasive surgical sperm retrieval technique used in men with azoospermia — the complete absence of sperm in ejaculated semen. The procedure involves inserting a fine needle attached to a syringe directly into the testis under local anaesthesia and applying gentle negative pressure to aspirate testicular tissue and fluid containing sperm. The retrieved material is then processed by an embryologist, and viable sperm are used for Intracytoplasmic Sperm Injection (ICSI) — a form of in-vitro fertilisation in which a single sperm is injected directly into a mature egg.

TESA was first described in the early 1990s and rapidly became a standard tool in male fertility management. It is distinct from Testicular Sperm Extraction (TESE), which involves making a small open incision in the scrotum to obtain testicular tissue, and from Percutaneous Epididymal Sperm Aspiration (PESA), which retrieves sperm from the epididymis. TESA is technically simpler and less invasive than TESE, making it the preferred first-line approach in obstructive azoospermia where sperm production in the testis is preserved but the transport pathway (vas deferens, epididymis) is blocked.

Male factor infertility contributes to approximately 40–50% of all infertility cases, and azoospermia is found in about 10–15% of infertile men. TESA, combined with ICSI, has transformed the prognosis for many of these men, enabling biological fatherhood when no ejaculated sperm are obtainable by any other means. Understanding the procedure, its indications, and realistic success expectations is essential for couples navigating the fertility treatment journey.

TESA is indicated across a range of clinical scenarios involving absent or severely impaired sperm in the ejaculate:

• Obstructive azoospermia (OA): The testes produce sperm normally, but a mechanical blockage prevents sperm from reaching the ejaculate. Causes include prior vasectomy, congenital bilateral absence of the vas deferens (CBAVD — associated with cystic fibrosis mutations), epididymal obstruction from past infection or trauma, and failed vasectomy reversal. TESA retrieval rates in OA exceed 90–100%, making it highly reliable in this group.
• Non-obstructive azoospermia (NOA): The testes have impaired or absent sperm production due to intrinsic failure. Causes include Klinefelter syndrome (47,XXY), Y-chromosome microdeletions (AZFc region), cryptorchidism, chemotherapy or radiotherapy exposure, orchitis, and idiopathic testicular failure. Sperm retrieval with TESA in NOA is variable (20–60%), and micro-TESE is often preferred in this context due to its higher sperm retrieval rate.
• Severe oligozoospermia: When ejaculated sperm count is extremely low and unpredictable, testicular sperm retrieval provides a reliable source for ICSI cycles.
• Retrograde ejaculation unresponsive to medical therapy: Men in whom sperm travel backward into the bladder during ejaculation and urine processing fails to retrieve usable sperm may benefit from direct testicular retrieval.
• Spinal cord injury and anejaculation: Men unable to ejaculate due to spinal cord injury, multiple sclerosis, or surgical trauma to pelvic nerves; TESA provides sperm retrieval when electroejaculation yields insufficient sperm.
• Men with high sperm DNA fragmentation in ejaculate: Some fertility centres prefer testicular sperm (which shows lower DNA fragmentation than ejaculated sperm) for ICSI in couples with repeated IVF failure or recurrent miscarriage.

Appropriate patient selection maximises the likelihood of successful sperm retrieval and optimises outcomes for the couple as a whole:

• Confirmed azoospermia: Two separate semen analyses (collected at least 4–6 weeks apart) showing a complete absence of sperm on extended centrifugation are required before recommending surgical sperm retrieval. The distinction between obstructive and non-obstructive azoospermia — determined by serum FSH, LH, testosterone, testicular volume on ultrasound, and sometimes genetic testing (karyotype, Y-chromosome microdeletion assay) — critically influences which retrieval technique is most appropriate.
• Partner has retrievable/healthy eggs: TESA sperm must be used with ICSI-IVF, so the female partner's ovarian reserve and uterine status must be assessed. Couples where both partners have significant fertility challenges require counselling about cumulative IVF success rates.
• Normal or mildly abnormal testicular function (for TESA specifically): Men with obstructive azoospermia and normal FSH/LH have the best prognosis with TESA. Men with severely elevated FSH (>20 IU/L) and small testes suggesting primary testicular failure are more likely to need micro-TESE rather than standard TESA.
• Medical fitness: Patients must be fit for minor scrotal surgery under local anaesthesia. Those on anticoagulants should have these managed appropriately before the procedure. Active scrotal infection is a temporary contraindication.
• Genetic counselling completed (where indicated): Men with Y-chromosome microdeletions (particularly AZFa or AZFb deletions — which have near-zero retrieval rates) or Klinefelter syndrome should receive genetic counselling before TESA, as some conditions carry transmission risk to male offspring.
• Psychological preparedness: Couples should be counselled about the possibility that TESA may not retrieve viable sperm (particularly in NOA) and that a back-up plan (donor sperm, adoption) should be discussed in advance.

Multiple surgical sperm retrieval techniques exist; the choice depends on the underlying cause of azoospermia, prior surgical history, and centre expertise:

Standard TESA (Aspiration)

Performed under local anaesthesia (1–2% lidocaine injected into the spermatic cord as a cord block and subcutaneously into the scrotal skin). A 21–23 gauge needle attached to a 10–20 ml syringe is inserted through the scrotal skin directly into the testis at its equatorial plane. Negative pressure is applied while the needle is moved back and forth in a "fan" pattern to aspirate cells. Multiple needle passes through different areas of the same testis improve yield. The procedure takes approximately 15–30 minutes. Retrieved material is immediately handed to an embryologist in theatre for rapid microscopic assessment under a warm-stage microscope. If sufficient sperm are found, the partner's egg retrieval can proceed on the same day (fresh TESA-ICSI) or sperm can be cryopreserved for a future thaw cycle.

TESA-Biopsy (TESA + Biopsy)

When initial needle aspiration yields inadequate material, a small incisional biopsy of the testicular parenchyma may be obtained through the same entry point or a 3–5 mm mini-incision. This hybrid approach bridges TESA and TESE and is useful when aspiration is initially unsuccessful.

Testicular Sperm Extraction (TESE — Open)

A 2–3 cm transverse scrotal incision is made under general or spinal anaesthesia, the tunica albuginea is incised, and one or more pieces of testicular parenchyma are excised. The tissue is minced and processed for sperm. TESE is more invasive than TESA but provides more tissue and higher sperm retrieval in difficult cases of NOA.

Microsurgical TESE (micro-TESE)

The current gold standard for non-obstructive azoospermia. Under high-powered operating microscopy (×16–25 magnification), dilated seminiferous tubules — which are more likely to contain foci of active spermatogenesis — are selectively identified and extracted. Micro-TESE achieves sperm retrieval rates of 40–60% in NOA compared to 20–40% with conventional TESE, while removing less testicular tissue. Requires significant surgical expertise and a centre with real-time embryology support.

Percutaneous Epididymal Sperm Aspiration (PESA)

A needle is inserted directly into the epididymis to aspirate epididymal fluid and sperm. Suitable for obstructive azoospermia with dilated epididymides (e.g., post-vasectomy). Yields mature epididymal sperm with higher motility than testicular sperm, but requires a palpably dilated epididymis and thus has narrower indications than TESA.

Sperm Cryopreservation

Retrieved testicular sperm can be cryopreserved (frozen) for use in future ICSI cycles. Cryopreservation allows retrieval and storage to be scheduled independently of the female partner's IVF stimulation cycle, reducing coordination pressure and providing a back-up supply if a future TESA attempt fails.

TESA offers substantial advantages as a sperm retrieval strategy for azoospermic men:

• Minimally invasive and outpatient: The needle-based technique requires only local anaesthesia, avoids general anaesthesia in most cases, and patients return home within 1–2 hours with a simple scrotal support and ice pack protocol.
• High success rate in obstructive azoospermia: Sperm retrieval exceeds 90% in men with obstructive causes, giving most men who have had a vasectomy or CBAVD a realistic chance of biological fatherhood without vasectomy reversal surgery.
• Enables biological fatherhood otherwise impossible: For men with azoospermia, TESA combined with ICSI is the only pathway to having a biologically related child without donor sperm.
• Rapid recovery: Most men return to sedentary work within 24–48 hours and to physical activity within 5–7 days, with minimal disruption to daily life.
• Concurrent or cryo cycle flexibility: Sperm can be retrieved and used fresh on the day of egg retrieval (maximising sperm function) or cryopreserved for use in planned future cycles — offering logistical flexibility for the couple.
• Lower DNA fragmentation than ejaculated sperm: Testicular sperm bypass the post-testicular epididymal transport during which oxidative stress accumulates, resulting in lower DNA fragmentation indices that may improve embryo quality in men with high ejaculatory sperm DNA damage.
• Minimal impact on future testicular function: When performed with fine-gauge needles by experienced practitioners, TESA causes minimal parenchymal damage, preserving testosterone production and future fertility options.

TESA is generally well-tolerated and safe; however, patients should be aware of the following potential complications:

• Pain and discomfort: Mild scrotal pain and discomfort are expected for 2–5 days post-procedure. Most men manage with over-the-counter analgesics (paracetamol or ibuprofen). Severe or worsening pain beyond 5 days warrants medical review.
• Scrotal haematoma: Blood accumulation in the scrotal tissue occurs in approximately 2–5% of cases and is the most common complication. Most haematomas resolve spontaneously over 2–4 weeks; large haematomas may require surgical drainage. Scrotal support and ice application for 24–48 hours post-procedure reduce this risk.
• Infection: Scrotal or epididymo-orchitis occurs in less than 1% of procedures with proper aseptic technique. Prophylactic antibiotics are routinely administered in most centres.
• Sperm retrieval failure: In men with non-obstructive azoospermia, there is a meaningful risk (40–80% depending on aetiology) that no viable sperm will be found. Couples must be counselled about this possibility and alternative options (donor sperm, adoption, embryo adoption) discussed prospectively.
• Testicular atrophy: Repeated TESA procedures or haematoma formation can theoretically cause progressive testicular scarring and atrophy, though this is uncommon with modern fine-needle techniques. Testosterone levels are rarely affected by a single well-performed TESA.
• Vascular injury: Needle injury to testicular vasculature is rare but can compromise local blood supply. Doppler ultrasound guidance reduces this risk in specialised centres.
• Anaesthetic complications: Allergic reactions to lidocaine are rare. Vasovagal reactions (fainting) during scrotal manipulation can occur in anxious patients and are managed by positioning and oral hydration before the procedure.

Patients should receive clear written post-procedure instructions covering scrotal support, activity restrictions, signs of complications, and emergency contact details for the fertility centre.

Post-procedural care and coordination with the IVF team are integral to the overall treatment success:

Immediate Post-Procedure (Day 0–3)

Patients are discharged with a scrotal support/jockstrap and ice pack protocol (20 minutes on, 20 minutes off for the first 6 hours). Oral analgesics (ibuprofen 400 mg three times daily with food, or paracetamol 500–1,000 mg four times daily) are prescribed for 3–5 days. Patients are advised to avoid strenuous physical activity, sexual intercourse, and submerging the scrotum in water (baths, swimming) for 5–7 days. A follow-up call or review at 24–48 hours checks for signs of haematoma or infection.

Embryology and Sperm Processing

Retrieved testicular tissue is processed immediately in the embryology laboratory. Motile sperm are identified under high magnification and selected for ICSI. Excess sperm are cryopreserved in multiple straws using a validated testicular sperm freezing protocol, providing backup for future cycles. Couples receive a summary of sperm retrieval outcome — quantity, motility, and cryopreservation status — usually within 24–48 hours of the procedure.

IVF-ICSI Cycle Coordination

If TESA was performed "fresh" (same day as egg retrieval), fertilisation results are available within 18–24 hours of ICSI. Embryo development is assessed over 3–5 days, and transfer of the highest-quality blastocyst typically occurs on day 5. If sperm were cryopreserved for a planned cycle, the female partner begins ovarian stimulation, and a thaw TESA sperm sample is prepared on the day of egg retrieval.

Long-Term Monitoring

Men with non-obstructive azoospermia or those who underwent multiple TESA procedures should have annual assessment of serum testosterone and LH/FSH to detect any progressive decline in testicular endocrine function, though this is uncommon with modern minimal-access techniques.

TESA costs cannot be considered in isolation — they are part of the broader IVF-ICSI treatment package. Cost factors include:

• TESA procedure alone: USD 500–1,500 in the United States; USD 300–800 in India; USD 400–1,000 in Thailand or Malaysia. This typically covers the urologist fee, local anaesthesia, embryology processing time for fresh sperm assessment, and basic scrotal support.
• Sperm cryopreservation: USD 300–700 for freezing; USD 200–500 per year for storage. Essential if the procedure is planned ahead of an IVF cycle or as a back-up.
• ICSI-IVF cycle: The major cost driver. A full IVF-ICSI cycle costs USD 12,000–20,000 in the United States, USD 2,500–5,000 in India, USD 4,000–8,000 in Thailand, and USD 5,000–10,000 in Europe. These costs include ovarian stimulation medications, monitoring, egg retrieval, embryology (ICSI, culture), and embryo transfer.
• Genetic testing (PGT-A/PGT-M): If preimplantation genetic testing is recommended (e.g., Klinefelter syndrome, Y-deletion carriers), an additional USD 3,000–6,000 per cycle applies.
• Multiple cycle costs: Success rates per IVF cycle vary by female partner's age (30–40% per cycle under 35; 15–25% at 38–40). Couples may require 2–3 cycles for success, multiplying overall costs.

Insurance coverage for TESA and IVF varies widely. In the United States, 19 states mandate some level of infertility coverage; in the UK, NHS funding is available in certain criteria. Medical tourism to India, Czech Republic, Spain, and Thailand offers substantially reduced costs without significant compromise in success rates at accredited centres. Patients should request itemised cost breakdowns and ask specifically about what is included in any quoted "package" price.

For men with azoospermia, several alternative sperm retrieval strategies and fertility pathways exist:

• Microsurgical TESE (micro-TESE): The gold standard for non-obstructive azoospermia. Higher sperm retrieval rates (40–60% vs 20–40% with TESA) but requires general anaesthesia, a longer procedure, and specialist microsurgical expertise. Preferred when TESA has previously failed in NOA.
• PESA (Percutaneous Epididymal Sperm Aspiration): Sperm aspiration from the epididymis; yields more motile sperm in obstructive azoospermia with dilated epididymides. An alternative to TESA in post-vasectomy men with good epididymal dilation.
• Vasectomy reversal (vasovasostomy / vasoepididymostomy): Microsurgical reconstruction of the vas deferens or epididymis can restore natural sperm flow and ejaculation. Success rates (50–90%) depend on time since vasectomy; younger intervals yield better outcomes. Avoids IVF cost if successful. Best discussed alongside TESA so couples can weigh natural conception vs. IVF pathways.
• Hormonal stimulation before retrieval: Men with hypogonadotropic hypogonadism (e.g., Kallmann syndrome) may be treated with gonadotropin injections (FSH + hCG) for 3–6 months to stimulate spermatogenesis before TESA, improving retrieval rates significantly.
• Donor sperm (DI — Donor Insemination or IVF with donor sperm): When TESA fails or genetic conditions (e.g., AZFa/AZFb deletions, Klinefelter with failed retrieval) make biological fatherhood impossible, donor sperm insemination (IUI) or IVF with donor sperm offers high success rates (50–80% per cycle with young egg provider) and avoids the invasiveness of surgical retrieval.
• Embryo adoption: Couples who are not candidates for either partner's own gametes can adopt donated embryos, offering a pregnancy experience without genetic connection.

Couples should receive comprehensive counselling from a reproductive endocrinologist and reproductive urologist working together to select the most appropriate pathway based on the specific diagnosis, female partner's fertility profile, and the couple's personal values and preferences.